Hematologic Malignancy
B-Cell Neoplasm
CI-CAN-00000470Explore in graph →
HematologicNon-malignant2,098 active trials46 approved drugs301 evidence items
- NCIt
- C27907
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000470Explore in graph →
Clinical trials
7,503 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07369895 | Clinical Study of O&D-001 Injection in the Treatment of Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 | 18 | O&D BioTech Group CO., LimitedINDUSTRY | 1 | Jan 27, 2026 | clinicaltrials |
| NCT05665530 | A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies | completed | Phase 1 | 86 | Prelude TherapeuticsINDUSTRY | 10 | Jan 26, 2026 | clinicaltrials |
| NCT07367685 | Clinical Study of Universal CD19 CAR-γδT Cell Injection in the Treatment of Adult Relapsed/Refractory B-cell Lymphoma | not yet recruiting | Phase 1 | 6 | The Second Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | Jan 26, 2026 | clinicaltrials |
| NCT04855695 | Avo In R/R And Previously Untreated MCL | recruiting | Phase 1 / Phase 2 | 72 | Austin I KimOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT04223765 | Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. | recruiting | Phase 1 | 20 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT04586426 | A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma(RedirecTT-1) | active not recruiting | Phase 1 / Phase 2 | 228 | Janssen Research & Development, LLCINDUSTRY | 7 | Jan 16, 2026 | clinicaltrials |
| NCT05222555 | Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients(MINDway) | active not recruiting | Phase 1 / Phase 2 | 53 | Incyte CorporationINDUSTRY | 9 | Jan 16, 2026 | clinicaltrials |
| NCT04855253 | Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL | suspended | Phase 1 / Phase 2 | 30 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT07334574 | Clinical Study of XP-006 mRNA Vaccine for R/R B-NHL(XP-006) | not yet recruiting | Phase 1 | 20 | Ruijin HospitalOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT07333430 | Study of Naive HBI0101 CAR-T Therapy in Relapsed/Refractory Multiple Myeloma | recruiting | Phase 1 | 60 | Hadassah Medical OrganizationOTHER | 1 | Jan 12, 2026 | clinicaltrials |
| NCT04134117 | Tisagenlecleucel In Primary CNS Lymphoma | completed | Phase 1 | 13 | Matthew J. Frigault, M.D.OTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT05211336 | Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System | active not recruiting | Phase 1 | 14 | National Cancer Institute (NCI)NIH | 1 | Jan 8, 2026 | clinicaltrials |
| NCT05464329 | Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Patients With Relapsed/Refractory Aggressive B Cell Lymphoma | active not recruiting | Phase 1 | 24 | Washington University School of MedicineOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT04572763 | Copanlisib Plus Venetoclax in R/R DLBCL | active not recruiting | Phase 1 / Phase 2 | 48 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT04843904 | Safe Accelerated Venetoclax Escalation in CLL(SAVE) | active not recruiting | Phase 1 | 40 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT03702725 | Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma | completed | Phase 1 | 14 | Alliance Foundation Trials, LLC.OTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT07071909 | Immune Reconstitution Monitoring and Pneumococcal Vaccination in Patients Treated With CAR-T Cells | withdrawn | Phase 1 / Phase 2 | 0 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT07316920 | A Clinical Study of of RN1701 Injection in the Treatment of Relapsed/Refractory B-Cell Lymphomas | not yet recruiting | Phase 1 | 19 | YANRU WANGOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT01853631 | Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)(SAGAN) | recruiting | Phase 1 | 64 | Baylor College of MedicineOTHER | 1 | Jan 5, 2026 | clinicaltrials |
| NCT07093554 | Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma | recruiting | Phase 1 | 31 | Medical College of WisconsinOTHER | 1 | Jan 5, 2026 | clinicaltrials |
| NCT06106841 | TQB3909 Tablets in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL) | terminated | Phase 1 / Phase 2 | 19 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 30, 2025 | clinicaltrials |
| NCT04123418 | A Study of WVT078 in Patients With Multiple Myeloma (MM) | terminated | Phase 1 | 56 | Novartis PharmaceuticalsINDUSTRY | 8 | Dec 24, 2025 | clinicaltrials |
| NCT04155710 | Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL | completed | Phase 1 | 7 | Iovance Biotherapeutics, Inc.INDUSTRY | 1 | Dec 24, 2025 | clinicaltrials |
| NCT06022029 | A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.(ON-5001) | recruiting | Phase 1 | 168 | OncoNano Medicine, Inc.INDUSTRY | 2 | Dec 24, 2025 | clinicaltrials |
| NCT07166549 | Bispecific CAR T Cells for B-cell Malignancies (BaseCAR-01 Trial)(BaseCAR-01) | not yet recruiting | Phase 1 | 12 | University Hospital, Basel, SwitzerlandOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT06392477 | A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Relapsed/ Refractory B-Cell Non-Hodgkin Lymphoma | recruiting | Phase 1 | 96 | SanofiINDUSTRY | 5 | Dec 23, 2025 | clinicaltrials |
| NCT01665794 | Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 25 | University of ChicagoOTHER | 2 | Dec 22, 2025 | clinicaltrials |
| NCT02296918 | Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL | completed | Phase 1 | 69 | Acerta Pharma BVINDUSTRY | 1 | Dec 19, 2025 | clinicaltrials |
| NCT05775094 | A Study of Romosozumab in Women With Multiple Myeloma and Osteoporosis | active not recruiting | Phase 1 | 10 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT05192122 | Free From Maintenance Drug Therapy in Multiple Myeloma (The FREEDMM Trial) for Minimal Residual Disease (MRD(HEME-20) | recruiting | Phase 1 | 50 | University of Illinois at ChicagoOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT02860676 | Extension Study of UC-961 (Cirmtuzumab) for Patients With Chronic Lymphocytic Leukemia Treated Previously With UC-961 | completed | Phase 1 | 3 | University of California, San DiegoOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT05317936 | Pirtobrutinib (LOXO-305) Consolidation for MRD Eradication in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) Treated With Venetoclax | terminated | Phase 1 / Phase 2 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT07052695 | Mosunetuzumab for CLL MRD Clearance | recruiting | Phase 1 / Phase 2 | 40 | Inhye AhnOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT03698552 | ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia | terminated | Phase 1 / Phase 2 | 37 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 12, 2025 | clinicaltrials |
| NCT05182073 | FT576 in Subjects With Multiple Myeloma | completed | Phase 1 | 31 | Fate TherapeuticsINDUSTRY | 1 | Dec 12, 2025 | clinicaltrials |
| NCT06518551 | Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM | recruiting | Phase 1 / Phase 2 | 49 | Omar Nadeem, MDOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT07179679 | A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell Tumors | recruiting | Phase 1 | 42 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 11, 2025 | clinicaltrials |
| NCT05602363 | AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma | recruiting | Phase 1 | 120 | Carna Biosciences, Inc.INDUSTRY | 1 | Dec 10, 2025 | clinicaltrials |
| NCT02328014 | Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies | completed | Phase 1 / Phase 2 | 40 | Acerta Pharma BVINDUSTRY | 1 | Dec 9, 2025 | clinicaltrials |
| NCT04184050 | Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (MK-4002-001) | active not recruiting | Phase 1 | 100 | Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 3 | Dec 5, 2025 | clinicaltrials |
| NCT04398680 | A Study of Belantamab Mafodotin in Multiple Myeloma Participants With Normal and Impaired Hepatic Function(DREAMM 13) | withdrawn | Phase 1 | 0 | GlaxoSmithKlineINDUSTRY | 3 | Dec 4, 2025 | clinicaltrials |
| NCT05065866 | Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy | completed | Phase 1 | 14 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT06645678 | Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma(MELT-MM) | recruiting | Phase 1 / Phase 2 | 75 | YOUNGIL KOHOTHER | 2 | Dec 3, 2025 | clinicaltrials |
| NCT04787263 | CD19-CAR_Lenti T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and DLBCL or PML | active not recruiting | Phase 1 / Phase 2 | 32 | Bambino Gesù Hospital and Research InstituteOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT05618327 | Phase I Clinical Study of JS203 in Patients With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma | active not recruiting | Phase 1 | 104 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT06080191 | Allogeneic Second-generation CD19-CAR T Cells for Pediatric Relapsed/Refractory B-ALL | recruiting | Phase 1 | 24 | Bambino Gesù Hospital and Research InstituteOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT06295549 | Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma | terminated | Phase 1 | 11 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Dec 1, 2025 | clinicaltrials |
| NCT02302469 | Study of Lenalidomide in Relapse/Refractory Waldenstrom Macroglobulinemia(RV-WM-0426) | completed | Phase 1 / Phase 2 | 17 | University Hospital, LilleOTHER | 1 | Nov 28, 2025 | clinicaltrials |
| NCT04091126 | Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma(DREAMM 9) | active not recruiting | Phase 1 | 118 | GlaxoSmithKlineINDUSTRY | 10 | Nov 28, 2025 | clinicaltrials |
Data updated 24 days agoSource updated Jan 27, 2026source: clinicaltrials